Drug
Ft536
Ft536: highest development phase Phase 1, developed by Fate Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Fate Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| FT536 NCT05395052 | Phase 1 | Non Small Cell Lung Cancer |
| FT536 NCT07560865 | Phase 1 | Astrocytoma |
Latest
No recent events.
Follow Ft536 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.